Mirae Asset Global Investments Co. Ltd. Acquires 541 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Mirae Asset Global Investments Co. Ltd. grew its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 21.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,078 shares of the company’s stock after acquiring an additional 541 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $58,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock worth $117,262,000 after acquiring an additional 591,631 shares in the last quarter. Sofinnova Investments Inc. increased its holdings in shares of Syndax Pharmaceuticals by 33.9% in the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock worth $44,215,000 after acquiring an additional 545,129 shares in the last quarter. StemPoint Capital LP increased its holdings in shares of Syndax Pharmaceuticals by 0.6% in the first quarter. StemPoint Capital LP now owns 1,100,988 shares of the company’s stock worth $26,204,000 after acquiring an additional 6,494 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Syndax Pharmaceuticals by 56.3% during the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock worth $21,875,000 after buying an additional 383,634 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new position in shares of Syndax Pharmaceuticals during the first quarter worth about $23,159,000.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Citigroup increased their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America increased their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. UBS Group initiated coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $35.90.

Syndax Pharmaceuticals Trading Up 4.0 %

NASDAQ:SNDX opened at $19.69 on Wednesday. The stock has a market cap of $1.68 billion, a P/E ratio of -5.83 and a beta of 0.92. The stock has a 50 day simple moving average of $19.05 and a 200 day simple moving average of $20.31. Syndax Pharmaceuticals, Inc. has a 1-year low of $13.14 and a 1-year high of $25.34.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).